Get the Stockscreener App
0.2106
0.57%
-0.0012
Ernexa Therapeutics Inc stock is traded at $0.2106, with a volume of 723.84K.
It is down -0.57% in the last 24 hours and down -28.12% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$0.2118
Open:
$0.2118
24h Volume:
723.84K
Relative Volume:
0.54
Market Cap:
$6.14M
Revenue:
$1,000
Net Income/Loss:
$-14.08M
P/E Ratio:
-0.1907
EPS:
-1.1043
Net Cash Flow:
$-7.05M
1W Performance:
-28.37%
1M Performance:
-28.12%
6M Performance:
-81.20%
1Y Performance:
-94.27%
1-Day Range:
$0.201
$0.2151
1-Week Range:
$0.201
$0.2917
52-Week Range:
$0.201
$4.0185
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.2106 | 6.17M | 1,000 | -14.08M | -7.05M | -1.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
Ernexa Therapeutics Inc. Files Form 8-K: Notice of Nasdaq Delisting and Company Response – March 2026 - Minichart
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price By Investing.com - Investing.com India
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price - Investing.com Australia
Ernexa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Resistance Check: Is PAVmed Inc stock a value trap2026 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
AI Stocks: Why is Ernexa Therapeutics Inc stock going upTrade Risk Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
Ernexa Therapeutics Inc may offer up to $50 million of securitiesSEC filing - marketscreener.com
Ernexa Therapeutics IncMay Offer Up To $50 Million Of SecuritiesSEC Filing - TradingView
Ernexa Therapeutics Inc. 2025 Annual Report: Synthetic Allogeneic iMSC Therapy, Business Overview, Key Risks, and Patent Portfolio - Minichart
Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M - TradingView
Ernexa Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aug Wrap: Is Ernexa Therapeutics Inc exposed to currency risksPortfolio Growth Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ernexa Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Sentiment: What is Ernexa Therapeutics Incs book value per shareJuly 2025 Price Swings & Accurate Entry/Exit Alerts - baoquankhu1.vn
Breakout Move: Is Ernexa Therapeutics Inc a strong candidate for buy and holdJuly 2025 Institutional & Pattern Based Trade Signal System - baoquankhu1.vn
Ernexa Therapeutics Inc.Common Stock (NQ: ERNA - FinancialContent
Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
ERNA Technical Analysis & Stock Price Forecast - Intellectia AI
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosure - The Globe and Mail
Ernexa Therapeutics updates investor presentation, posts Exhibit 99.1 on website - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) furnishes new February 2026 investor presentation - Stock Titan
Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell? - Defense World
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Will Ernexa Therapeutics Inc. stock outperform value stocksQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Ernexa therapeutics ten percent owner Cherington buys $2m in stock By Investing.com - Investing.com India
Ernexa therapeutics ten percent owner Cherington buys $2m in stock - Investing.com
ERNA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Ernexa Therapeutics Inc. outperform tech stocksJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Can Ernexa Therapeutics Inc. continue delivering strong returnsQuarterly Trade Review & Capital Efficiency Focused Strategies - mfd.ru
Will Ernexa Therapeutics Inc. stock remain a Wall Street favoriteWeekly Market Outlook & Short-Term High Return Ideas - mfd.ru
Will Ernexa Therapeutics Inc. stock benefit from green energy trendsTrade Volume Summary & Accurate Buy Signal Notifications - mfd.ru
Eterna Therapeutics Completes Public Offering to Bolster Capital - TipRanks
Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView
Profit Review: Can Ernexa Therapeutics Inc. be recession proofWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
What hedge fund activity signals for Ernexa Therapeutics Inc. stockJuly 2025 PostEarnings & Target Return Focused Picks - mfd.ru
Total debt of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Ernexa Therapeutics prices $10.5 million public offering at $0.50 per share - Investing.com
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - The Manila Times
Ernexa Therapeutics Inc. Announces Pricing of $10.5 Million Public Offering of Common Stock and Warrants - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Street Watch: Is Ernexa Therapeutics Inc forming bullish engulfing patternsQuarterly Investment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Valuation Update: Why is Ernexa Therapeutics Inc stock going up2025 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA - Quiver Quantitative
Ernexa Therapeutics Participates in Virtual Investor “What - GlobeNewswire
Japanese trade program selects Ernexa Therapeutics among elite biotech group - Investing.com Canada
Ernexa Therapeutics Selected for Japan Entry Acceleration Program to Advance Innovative Cell Therapies - Quiver Quantitative
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):